No. 3 pharmacy retailer Rite Aid gets kudos for righting the ship, but the easy money has already been made.
With a presence in 21 states already, LifePoint Hospitals Inc. is likely to move beyond its typical rural realm and penetrate suburban markets in the future.
Conatus Pharmaceuticals is an early-stage developer of drugs to treat diseases of the liver with a favorable risk-reward profile, particularly after recent investor selling in the biotech sector has created some nice values.
Small business owners are increasingly saying that Obamacare will boost the national economy by safeguarding the health of their employees and freeing them up to focus on strategic business growth.
An inside look at how Intuitive Surgical botched the upgrade cycle for its high-price surgical robots.
If approved next year, Alkermes' aripiprazole lauroxil will compete against several other long-acting antipsychotics, including a similar once-monthly injectable aripiprazole approved last year and sold by Otuska and Lundbeck. But the schizophrenia treatment market (oral and injectable drugs) is big and growing -- more than $11 billion in the U.S. last year and $20 billion-plus worldwide. Oral versions of aripiprazole, sold under the brand name Abilify, generated $6.5 billion in sales last year.
By Bret Jensen
A pullback of at least 10%, seems like a distinct possibility.
U.S. stock futures point to a slight rebound on Wall Street; Citigroup to pay $1.13 billion to settle mortgage claims; Japan's Takeda and Eli Lilly are ordered to pat $9 billion in diabetes-drug case; Alcoa to report earnings on Tuesday.
Long-term care, and the insurance to pay for it, have broken financial models.
Some consumers may still have coverage options, especially if their online registration got started before March 31.
Patients with advanced blood cancer respond to treatment with Agios' AG-221, according to study results presented Sunday.
U.S. stock futures point lower amid a selloff in technology shares; India's Sun Pharmaceutical to buy Ranbaxy; BlackRock shakes up top management; Holcim and Lafarge to merge; Yahoo! makes a push into video content, says a report.
Biotech columnist Adam Feuerstein answers readers' questions about health care companies.
The Affordable Care Act's strategy was as sound as its initial execution was weak.
The biotech sector's March "fluctuation" might be a temporary speed bump or the beginning of a longer downturn. Either way, investors can still count on the biotech catalyst trade for chills and thrills.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV